首页> 外文期刊>NeuroImage: Clinical >Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease
【24h】

Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease

机译:在腹侧腹侧腹膜内的铁沉积增加了NIGRA PARSCACTCA:帕金森病的一个有希望的神经影像标记

获取原文
       

摘要

BackgroundTo date there are no validated MRI biomarkers to assist diagnosis of Parkinson’s disease (PD). Our aim was to investigate PD related iron changes in the substantia nigra pars compacta (SNpc) as defined by neuromelanin-sensitive MR contrast.MethodsThirty-nine PD participants and 33 healthy controls were scanned at 3.0-T using a 16-echo gradient echo sequence to create R2* maps for the evaluation of iron content to find the overlap with a neuromelanin based SNpc mask. The SNpc overlap percentage with the R2* map, and the R2* values in both the whole SNpc and the overlap volume were compared between PD and control groups, and correlated with clinical features for PD participants. Finally, the diagnostic performance of the SNpc overlap percentage was evaluated using ROC analysis.ResultsPD related iron changes mostly occur in the lateral-ventral part of the neuromelanin SNpc. The R2* values in the whole SNpc and the SNpc overlap volume, and the SNpc overlap percentage were larger in PD participants than in controls. Furthermore, the SNpc overlap percentage was positively correlated with the disease duration in PD. The SNpc overlap percentage provided excellent diagnostic accuracy for discriminating PD participants from controls (AUC?=?0.93), while the R2* values in the whole SNpc or the overlap volume were less effective.ConclusionThe overlap between the iron content as determined by R2* mapping and neuromelanin in the substantia nigra pars compacta has the potential to be a neuroimaging biomarker for diagnosing Parkinson’s disease.
机译:背景日期没有验证的MRI生物标志物,以协助诊断帕金森病(PD)。我们的目标是调查神经元敏敏敏感MR对比度的基础NIGRA PARSCACTA(SNPC)中的PD相关铁变化。使用16回声梯度回声序列,在3.0-T扫描了33名PD参与者和33名健康对照为了创建R2 *映射,用于评估铁含量,以找到基于神经元蛋白的SNPC掩模的重叠。 SNPC与R2 * MAP重叠百分比,并在PD和对照组之间比较整个SNPC和重叠体积中的R2 *值,并与PD参与者的临床特征相关联。最后,使用ROC分析评估SNPC重叠百分比的诊断性能。培训综合的铁变化主要发生在神经瘤素SNPC的侧面腹侧部分。整个SNPC和SNPC重叠卷中的R2 *值,并且SNPC重叠百分比在PD参与者中比在控制中更大。此外,SNPC重叠百分比与PD中的疾病持续时间呈正相关。 SNPC重叠百分比提供了极好的诊断准确性,用于区分PD参与者免受控制(AUC?= 0.93),而整个SNPC或重叠体积中的R2 *值较小。结论铁含量之间的重叠,如R2 *确定在体积NIGRA PARS Compacta中的测绘和神经瘤素有可能成为诊断帕金森病的神经影像生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号